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ABSTRACT: Myricetin is a natural flavonol found in many grapes, berries, fruits, vegetables, and herbs as well as other plants.
Recent studies have identified potential antiamyloidogenic activity for this compound. In this study, the kinetics of amyloid fibril
formation by hen egg white lysozyme (HEWL) and the antifibril-forming activity of myricetin were investigated. We demonstrate
that myricetin significantly inhibits the fibrillation of HEWL and the inhibitory effect is dose-dependent. Interestingly, the
inhibitory effect toward HEWL fibrillation was stronger than that exerted by the previously characterized fibril-forming inhibitor
quercetin, which has high structural similarity with myricetin. Spectrofluorometric and computational studies suggest that the
mechanism underlying the inhibitory action of myricetin at a molecular level is to reduce the population of partially unfolded
HEWL intermediates. This action is achieved by the tight binding of myricetin to the aggregation-prone region of the β-domain
of HEWL and linking to the relatively stable α-domain, thus resulting in the inhibition of amyloid fibril formation.
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■ INTRODUCTION
Amyloid diseases are characterized by conformational changes of
certain proteins, which lead to intracellular or extracellular
aggregation, eventually resulting in fibrillar amyloid deposits in
the affected tissue. Currently there are approximately 30
extracellular fibril proteins known to be associated with human
amyloidosis.1 The so-called “hereditary non-neuropathic sys-
temic amyloidosis” is associated with two lysozyme variants
(I56T and D67H), which were identified in the early 1990s2 and
other naturally occurring amyloidogenic variants (F57I, F57I/
T70N,W64R, and T70N/W112R) discovered more recently.3−5
The pathological characteristics of these amyloidoses includes
the deposition of the full-length protein variants in organs, such
as liver, spleen, and kidneys.2
At present there are still no effective treatments for amyloid
diseases such as Alzheimer’s disease, systemic amyloidosis,
familial amyloid polyneuropathy, and Creutzfeldt-Jakob disease,
and all drugs in development that target Alzheimer’s disease have
failed at various stages of clinical trials.6 However, the
identification and development of small molecules that inhibit
fibril formation by amyloidogenic proteins is a promising area of
research.7,8 Among the most promising small-molecule inhib-
itors, the naturally occurring polyphenols show themost effective
antiamyloidogenic activity.9 A group of polyphenols found in
green tea (GTPs) including (−)-epigallocatechin (EGC),
(−)-epicatechin gallate (ECG), and (−)-epigallocatechin gallate
(EGCG) have been reported as effective inhibitors of alkali-salt-
induced fibrillogenesis of hen egg white lysozyme (HEWL) with
ECG as the most potent polyphenol.10 A previous report
demonstrated that curcumin can also inhibit the aggregation and
formation of amyloid fibrillation of HEWL at pH 2.0 in a dose-
dependent manner.11 In addition, some other small molecules
have been demonstrated to show inhibitory effects on HEWL
amyloid fibril formation, such as acridine derivatives12−14 and
carnosinea common dipeptide in mammals.15 However, the
relative inhibitory effects between these small molecules are
difficult to compare systematically because of varied exper-
imental conditions including temperature, concentration of
protein, pH, and rotation speeds, applied by different research
groups. Along with relatively well characterized polyphenols such
as ECGC and curcumin, myricetin has also recently been
investigated for antiamyloidogenic activity (Figure 1).16
Myricetin has been shown to exhibit stronger inhibitory activity
against Aβ fibrillation compared to other flavonoids of similar
structures, including quercetin and luteolin, both of which
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Figure 1. Chemical structure of myricetin.
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possess fewer hydroxyl groups on the B ring.17 Although the
detailed molecular mechanisms underlying the inhibitory effects
of flavonoids remain unclear, these results suggest that
differences in hydroxyl groups contained within the flavonoid
structure may influence the formation of hydrogen bonds
between Aβ and its hydroxyl arms, and is possibly the key
determinant of antiamyloidogenic activity.17
Many of the currently investigated small-molecule inhibitors
act as general antiamyloid agents, which affect a range of
amyloidogenic proteins.18−20 Although the property of non-
specificity is typically not desirable for drug design, it can offer the
possibility of broad-spectrum therapeutics, but only provided
there is no effects on functional human fibrous proteins such as
those that constitute the cytoskeletal system. Currently myricetin
has been demonstrated as exhibiting antiamyloidogenic activity
against Aβ, α-synuclein, IAPP.17,21,22 We sought to assess further
the general nature of inhibitory activity by investigating whether
myricetin could inhibit fibril formation in vitro of hen egg white
lysozyme. HEWL has two domains, α and β, and each consists of
four α-helices and an antiparallel β-sheet. Its structure is highly
homologous to human lysozyme, which is responsible for the
formation of systemic amyloidosis.23
In this study, thioflavin T (ThT) fluorescence assays and
transmission electron microscopy (TEM) were used to detect
and assess the inhibitory activity of myricetin upon fibril
formation by HEWL. Additionally, the interaction between
myricetin and the monomeric form of HEWL was investigated
using a combination of anilinonaphthalene-8-sulfonic (ANS)
and intrinsic fluorescence assays coupled with in silico
simulations.
■ MATERIALS AND METHODS
Proteins and Reagents. HEWL was purchased from Solarbio
(Beijing, China). ThT, ANS, myricetin, and quercetin were purchased
from Sigma-Aldrich (St. Louis, MO, USA).
HEWL Sample Preparation. A stock solution of myricetin (50
mM) was prepared in dimethyl sulfoxide (DMSO). HEWL sample
solutions were prepared by dissolving 1 mg of HEWL powder in 1 mL of
50 mM glycine−hydrochloric acid buffer (pH 2.0) with or without an
aliquot of myricetin solution. The final concentration of DMSO in
HEWL sample solution is 0.2%, of which we confirmed that 0.2%
DMSO had no obvious effect on fibrillar structure and ThT
fluorescence. Incubation was carried out with constant agitation at
140 rpm at 65 °C during the course of aggregation.
Thioflavin T Fluorescence Assay. Phosphate buffer (50 mM
Na2HPO4, 50 mM NaH2PO4, pH 7.0) was used to dissolve ThT to a
stock concentration of 1 mM. Aliquots of HEWL samples taken at
different times were diluted with phosphate buffer (pH 7.0), followed by
the addition of an aliquot (30 μL stock solution) of ThT stock solution.
ThT fluorescencemeasurement was conducted by exciting the sample at
440 nm and recording the emission intensity at 485 nm over 120 s. The
measurement was carried out using a Cary Eclipse fluorescence
spectrophotometer (Varian, Palo Alto, CA, USA).
Intrinsic Fluorescence Assay. Steady state intrinsic fluorescence
spectrum was measured with a Cary Eclipse fluorescence spectropho-
tometer (Varian) using a quartz cuvette with a path length of 1 cm.
HEWL samples (30 μL) with or without myricetin were diluted to a final
volume of 3 mL and then subjected to analysis. The sample was excited
at 280 nm, and the spectrum was recorded between 300 and 500 nm.
ANS Fluorescence Assay. A stock solution of ANS (0.4 mM) was
prepared by dissolving ANS in phosphate-buffered saline (PBS; pH 7.0).
The ANS stock solution was stored at 4 °C. Aliquots of HEWL solution
with or without myricetin taken at different times were mixed with an
aliquot of ANS solution, followed by the addition of PBS (pH7.0) to a
final of volume of 3 mL. After incubation in the dark for 30 min at room
temperature, the samples were subjected to fluorescence assay using a
Cary Eclipse fluorescence spectrophotometer (Varian). The samples
were excited at 380 nm, and fluorescence was recorded between 400 and
600 nm. Both the ANS fluorescence intensity and the average emission
wavelength were recorded to account for the changes in intensity and
spectrum. We confirmed that myricetin had no obvious effects on ThT,
ANS, and intrinsic fluorescence.
Transmission Electron Microscopy. HEWL samples with and
without myricetin were diluted 5-fold, and 10 μL of each sample was
dispensed onto a coated copper-mesh grid. The grid was negatively
stained with 1% (w/v) phosphotungstic acid and then observed with a
Hitachi H-7650 transmission electron microscope with an accelerating
voltage of 80 kV.
Molecular Dynamic Simulations and Docking Studies. All
molecular dynamics (MD) simulations were carried out using the
GROMACS 4.0.7 software package.24 The crystal structure of HEWL
(PDB entry 1GXV) was downloaded from the Protein Data Bank
(PDB).25 The GROMOS96 43a126 force field was adopted in all
simulations in this study. The monomer model was solvated in a water
box containing 10,124 simple point-charge water molecules27 and
neutralized by adding eight Cl− counterions. The linear constraint solver
method27 was used to constrain the bond length, allowing for
integration time steps of 2 fs throughout the whole simulation.
Electrostatic interactions were calculated with the particle-mesh Ewald
algorithm.28 A cutoff of 9 Å was used for all calculations. The solvated
and neutralized systems were then energy-minimized for 20,000 steps to
remove bad contacts. Then the side chains and solvent were allowed to
move unrestrained for 40 ps, with the backbone atoms of the structure
fixed. To investigate the structural fluctuation of HEWL under amyloid
fibril forming conditions, MD simulations at 338 K and pH 2.0 were
carried out. For the control, a physiological condition of 310 K and pH
7.0 was used. After equilibration, two independent simulations were
carried out for 20 ns.
Docking studies were performed using Autodock 4.2.5.1. The 3D
structure of myricetin was obtained from TCM Database@Taiwan.29
Prior to autodocking the HEWL molecule and myricetin were prepared
using AutoDockTools 1.5.4, including addition of polar hydrogen atoms
and setting the charges of HEWL residues using Kollman charges and
adding Gasteiger charges to myricetin.
The docking grids were carried out with a default spacing value of
0.375 Å and a grid volume of 60 × 60 × 60 points covering the entire
surface of HEWL. The protein molecule was set to be rigid while the
ligand molecule was considered to be flexible. In the docking simulation,
a Lamarckian geneti algorithm was used to generate 50 binding models,
each of which was individually selected as the lowest binding energy
(calculated using the Autodock scoring function) among a maximum of
2,500,000 evaluations. These 50 complexes were clustered according to
their root-mean-square deviation (RMSD) values and binding energies
in order to distinguish the preferred binding model.
Statistical Analysis. All experiments were performed at least three
times, and all data are presented as means ± standard deviations (SDs).
Comparisons between groups were tested by one-way ANOVA analysis.
Statistical significances of data were considered at the P < 0.05 level.
■ RESULTS
Analysis of HEWL Fibril Formation Using ThT Fluo-
rescence.HEWL is a model protein for amyloid research as it is
known to readily form fibrils under conditions of low pH and
elevated temperature, when coupled with mechanical agitation.30
By monitoring the kinetics of HEWL fibril formation by
fluorescence spectroscopy, we found that the relative fluo-
rescence of HEWL increased with extended incubation times
(Figure 2A), which is in agreement with previous studies.31 The
consistent increase in ThT fluorescence intensity observed when
HEWL was incubated alone, demonstrates that formation of
amyloid fibrils proceeded rapidly and without a lag phase (Figure
2A). The inhibitory effect exerted on the formation of HEWL
fibril by the addition of myricetin (100 μM) into the assay
resulted in a strong inhibition of HEWL fibril formation (Figure
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2A). Compared to quercetin-containing HEWL samples (the
positive control group), myricetin showed a reproducible
moderately stronger inhibition.
To determine an effective concentration range of myricetin for
inhibiting HEWL fibril formation, varying aliquots of myricetin
were mixed with HEWL to final concentrations of 1, 10, and 100
μM; at these concentrations we did not observe significant toxic
effects of myricetin on cell survival (data not shown) and the
ThT fluorescence intensity measured (Figure 2B). Myricetin
(and quercitin control) was observed to exhibit a dose-
dependent effect on HEWL fibril formation (Figure 2B).
Although fibril inhibition was observed up to a concentration
of 10 μM, major inhibitory effects were only observed at a
concentration of 100 μM, indicating effective fibril inhibition
occurs between these two concentrations. Importantly, at 100
μM the inhibitory effect of myricetin on HEWL fibril formation
was significantly stronger (p-value = 0.037626 < 0.05) than that
previously obtained with quercetin (Figure 2B), the positive
control.
By calculating the percentage of protection from the ThT
curve of HEWL alone and fitting a logarithmic concentration−
response curve, myricetin inhibited HWEL fibril formation with
a median effective concentration (IC50 value) of 28.2 μM
(Figure 2C).
Assessing Structural Changes during HEWL Fibril
Formation. ANS is a fluorescencent dye that has high affinity
for the hydrophobic surfaces of proteins. Upon binding to the
hydrophobic regions of a protein surface, the intensity of the light
emission is increased, with the emission maximum showing a
blue shift.32 This technique allows changes in the hydrophobic
core and the stability of a whole protein to be monitored during
the course of aggregation. As shown in Figure 3A, a significant
blue shift from 515 to 473 nm and increase in intensity of ANS
fluorescence, compared to native HEWL, is caused by HEWL
fibril formation. The addition of 100 μM restores HEWL fibril
ANS intensity to levels comparable with the native protein.
Variation in the microenvironment of tryptophan residues and
monitoring the intrinsic fluorescence of a protein allow
assessment of structural characteristics.33 To further probe the
effect of myricetin on the conformation of HEWL, the intrinsic
fluorescence of HEWL in the absence or presence of myricetin
was measured. A decreased intensity in intrinsic fluorescence of
Figure 2. Effects of myricetin and quercetin on amyloid formation by
HEWL: (A) the kinetics of HEWL fibril formation in the absence (filled
squares) or the presence of myricetin (filled diamonds) or quercetin
(filled upward triangles) as monitored by ThT fluorescence; (B) dose-
dependent inhibitory capacity of myricetin and quercetin on amyloid
formation by HEWL 7 days after incubation; (C) dose−response curve
plotting the plateau value of the ThT fluorescence intensity of the
HEWL sample against myricetin concentration.
Figure 3. (A) ANS fluorescence emission spectra of HEWL fibril
incubated with (pink) or without (red) myrecetin after incubation for 7
days. (B) Intrinsic fluorescence emission spectra of HEWL fibril in the
absence (red) and presence (purple) of myricetin after incubation for 7
days.
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HEWL fibril group with a shift from 344 to 355 nm was observed
compared to the native HEWL group (Figure 3B). This indicated
that tryptophan in HEWL became more accessible to solvent
during the process of fibril formation, resulting in the quenching
of fluorescence by water.34,35 However, the presence of myricetin
significantly reduced the fluorescence intensity during fibril
formation (Figure 3B). The quenching of intrinsic fluorescence
may possibly result from the interactions between aromatic
residues of myricetin and the aromatic residues of target
proteins.36,37
Physical Analysis of HEWL Fibril formation. Direct
information on the formation of fibril by HEWL as well as by the
antifibrillogenic activity of myricetin was obtained using TEM.
The morphology of HEWL fibers and/or aggregates in the
absence or presence of myricetin is shown in Figure 4A−G. In
the absence of myricetin or quercetin, HEWL displayed straight
and regular premature or mature amyloid fibril structures with
typical diameters ranging from 2 to 20 nm and several
micrometers in length (Figure 4A,E). The presence of quercetin
(Figure 4B) clearly resulted in reduced amounts of HEWL fibrils.
In contrast, the presence of myricetin resulted in formation of
amorphous aggregates, with virtually no HEWL fibrils being
observed (Figure 4C). This result provides further evidence that
myricetin exhibits a stronger inhibition against fibril formation by
HEWL compared to quercetin. To elucidate the physical nature
of myricetin fibril inhibition, by using TEM we also examined
HEWL fibril formation and myricetin inhibition with prolonged
incubation time and found 25 μM myricetin (close to IC50
value) incubated with HEWL resulted in a reduced amount of
amyloid fibril after 12 days incubation (Figure 4G). In contrast,
the presence of 100 μM myricetin resulted in formation of
amorphous aggregates, with virtually no HEWL fibrils being
observed (Figure 4D). Taken together, we concluded that the
physical nature of fibril inhibition is determined by the
concentration of myricetin. We also confirmed that the TEM
images of myricetin at 100 μM show only the deposition of the
compound alone and no fibril structure was found (Figure 4H).
Computational Analysis of HEWL Fibril Formation.
Based on the spectrometric and electron microscopy data, it can
be inferred that myricetin inhibition of amyloid fibrils formation
of HEWL mainly occurs at a very early stage in the process. To
better understand the process of amyloid fibril formation by
HEWL as well as the interaction of myricetin with lysozyme at
the atomic level, we carried out MD simulations (see Materials
and Methods).
Figure 5A compares the degree of conformational changes that
occur in HEWL under two different MD simulation conditions,
one favoring amyloid fibril formation (338 K and pH 2.0) and the
other under normal cellular physiological parameters (310 K and
pH 7.0). The backbone RMSD trajectory in fibril-forming
condition (represented by the red trace) has a higher value,
indicating a less stable state than that in physiological conditions
(black trace). The root-mean-square fluctuation (RMSF) of each
residue (Figure 5B) revealed a major contribution of the β-
domain (residues from 36 to 87) toward the instability of HEWL
under fibril-forming conditions. This is consistent with the
dramatic changes of β-sheet content in the β-domain observed
during the 20 nsMD simulation, particularly the major difference
in stability observed after 15 ns compared to changes seen under
physiological conditions (Figure 5C). In contrast, the α-domain
maintained much of the native conformation with the content of
α-helix being constant (data not shown). From the superposition
of the final conformational state following the 20 ns MD
simulation, the clear disruption in the β-domain could be directly
observed (Figure 5D).
To investigate how myricetin may affect the conformation of
HEWL, we carried out docking simulations between these two
Figure 4. Transmission electron microscopic images of HEWL fibrils
formed in the absence or presence of myricetin or quercetin, after
incubation at 65 °C and pH 2.0 for 7 days or 12 days: (A) HEWL fibril
after incubation for 7 days; (B) HEWL fibril in the presence of 100 μM
quercetin; (C) images of HEWL in the presence of 100 μM myricetin
after incubation for 7 days; (D) images of HEWL in the presence of 100
μM myricetin after incubation for 12 days; (E) HEWL fibril after
incubation for 12 days; (F) images of HEWL in the presence of 10 μM
myricetin after incubation for 12 days; (G) images of HEWL in the
presence of 25 μMmyricetin after incubation for 12 days; (H) images of
100 μM myricetin after incubation for 12 days. Scale bars represent 1
and 2 μm.
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molecules. According to the docking results, myricetin was
located in an area between the α-domain and the β-domain
(Figure 6A). The predicted binding site for myricetin on HEWL
was clustered around many residues, such as Asn44, Asn46,
Asp52, Asn59 and Glu35, Ala107, Val109, and Trp62 and Trp63.
The interactions between myricetin and these residues were
through van der Waals interactions and hydrogen bonding. Of
particular note are the interactions with residues Trp62 and
Trp63 in the β-domain, which could explain the quenching of
intrinsic fluorescence (Figure 6B).
■ DISCUSSION
Amyloid diseases are either sporadic or familial in their nature.
Usually, in the sporadic forms of the diseases the aggregated
peptides/proteins display wild-type sequences, while in rarer
early onset familial forms of the diseases the aggregation results
from genetic mutations that exhibit a greater propensity for
aggregation.38 A major risk factor for most sporadic amyloid
diseases is aging.39 In older people, the age-related decline in
cellular proteostasis includes the unfolded protein response, the
ubiquitin proteasome system, autophagy, and the encapsulation
of damaged proteins in aggresomes, all of which lead to the
accumulation of protein aggregates.40−43 Progression of the
aging process means that most kinds of amyloid diseases occur
undetected in their early stages. However, an increasing number
of research investigations suggest that the intake of diets
containing natural small molecules with inhibitory activities
toward amyloid fibril formation may help to prevent such
diseases or at least delay early onset.44−46
Myricetin is a cell-permeable flavanoid often used in
inflammatory, diabetes, and cancer studies, since it has a variety
of pharmacological properties such as antioxidant activity and an
ability to reduce blood sugar levels.47,48 High-throughput screens
for small molecules exhibiting antiamyloidogenic activity
demonstrated that myricetin could prevent amyloid fibril
formation of Aβ, α-synuclein, and IAPP. To further develop
and characterize myricetin as a potential antiamyloid therapeutic
agent, we assessed the ability of this small molecule to inhibit
amyloid fibril formation by the model protein HEWL.
The inhibitory effect exerted by myricetin on HEWL fibril
formation, as assessed by ThT fluorescence, was greater than the
well-characterized polyphenol quercetin (Figure 2A). However,
Figure 5. (A) RMSD of the Cα-positions during the 20 ns simulations. (B) RMSF trajectory per residue during the period of MD simulations. (C)
Fluctuation of β-sheet content in β-domain through the 20 ns MD simulation. (D) Superposition of the final state of the 20 ns MD simulation at
physiological condition (black) and amyloid fibril forming condition (red).
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since ThT fluorescence induction can be biased by the presence
of exogenous compounds,49 we also assessed the physical nature
of myricetin fibril inhibition using TEM. Incubation of myricetin
with HEWL resulted in the formation of amorphous aggregates,
with little or no fibrils being observed (Figure 4C,D). This was in
contrast to incubation of HEWL in the presence of quercetin,
which resulted in a reduction of amyloid fibril formation, but no
formation of amorphous aggregates (Figure 4B). The results
from the TEM analysis therefore are in agreement with the ThT
assay and clearly demonstrate that myricetin inhibits HEWL
fibril formation more effectively than quercetin. While these
experiments reveal the inhibitory potential of myricetin against
amyloid fibrils, they do not provide any information regarding
the potential molecular mechanisms underlying this activity. In
an attempt to gain insight into the molecular nature of fibril
inhibition we turned to well-developed computational ap-
proaches.
Previous studies demonstrated that amyloidogenic variants of
human lysozyme such as I56T and D67H, undergo transient and
local cooperative unfolding in the β-domain region of the
protein, a process that occurs at the early stage of amyloid fibril
formation and under physiologically relevant conditions (pH and
temperature).50,51 Furthermore, the local unfolding of β-domain
is considered to be the main trigger for fibril formation.
Consistent with previous studies, we observed a similar
phenomenon during MD simulations carried out using wild-
type HEWL; that is, the localized unfolding of β-domain
appeared to be the key event in inducing fibril formation (Figure
5A−D).
According to Sugimoto and colleagues,52 a peptide located in
the β-domain of HEWL referred to as K peptide (consisting of
residues 54−62 GILQINSRW) was found to act as a core for
aggregation and subsequent amyloid fibril formation. Likewise,
Lara et al. recently found the shorter peptide sequence ILQINS
to be highly amyloidogenic at room temperature.53 This region
of the protein is partially embedded inside the HEWL structure
as a pocket in the junction connecting the α-domain and the β-
domain. Combined with results from previous studies, our
findings in this work indicated that the stability of this region in
the β-domain directly determines the aggregation fate of the
entire protein, dictating whether it proceeds to form amorphous
aggregates or amyloid fibril. Further understanding of the early
events in conformation changes that occur in HEWL unfolding
will not only allow a better understanding of the process of
HEWL fibril formation but may also enable development of
effective ways to inhibit amyloid fibril formation by reducing the
ability of HEWL to form locally unfolded intermediates.
Computational approaches to studying how molecules
interact are well-established.54,55 Applying computational
docking studies allowed the exploration of the mechanism of
myricetin-induced inhibition of HEWL fibril formation. The
smaller blue shift and reduced fluorescence intensity observed by
ANS fluorescence assay, an indicator of a less hydrophobic core
exposed to solvent, suggested that myricetin could stabilize the
whole conformation of HEWL even though it was subjected to
fibril-forming conditions (Figure 4A). The docking study
revealed that the HEWL binding site for myricetin is located in
the region that partly includes the K peptide located between the
α-domain and the β-domain (Figure 6A), the key region
associated with amyloid fibril formation. A plausible explanation
for the inhibitory action of myricetin is a reduction of locally
unfolded intermediates, which in turn will reduce the propensity
for amyloid fibril formation. In this binding mode, myricetin may
be acting as an adhesive via hydrogen bonding and van der Waals
interaction to glue the aggregation-prone region of the β-domain
with the otherwise stable α-domain, consequently resulting in a
reduced population of transiently β-domain unfolded inter-
mediates. Thus, no formation of amyloid fibril would occur
under this condition. However, further biophysical experimenta-
tion is required to fully address the mechanism of fibril inhibition.
Support for the authenticity of the binding site for myricetin,
derived from the docking study, is supported by the experimental
data from the intrinsic fluorescence assay. Results from the
intrinsic fluorescence assay showed that the interaction between
the aromatic residues of myricetin and HEWL could account for
the quenching of intrinsic fluorescence (Figure 3B). The
normalized fluorescence changes versus the different incubation
time appeared almost the same for the emission spectra obtained
from excitation at 280 and 295 nm (data not shown), indicating
that the quenching of fluorescence can be attributed to Trp
residues. Taken together with the fact that Trp62 is one of the
two dominant emitters (the other is Trp108),56 the binding site
which is located close to Trp62, identified by the docking study,
is very likely to be the real scenario. This is consistent with
previous investigations in which certain small molecules with
inhibitory activity towardHEWL fibril formation, such as EGCG,
EUK-8, and EUK-134 (two kinds of salen−manganese
complexes) were also suggested to bind to Trp62 and Trp63
in docking studies.10,57,58 Taken together, our findings provided
a plausible rationale by which fibril formation by HEWL could be
Figure 6. (A) Panoramic view showing the mode of binding between
myricetin and HEWL. (B) Close-up view of the complex showing the
binding between myricetin and HEWL, with hydrogen bonding marked
as a green dotted line.
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inhibited by small molecules by targeting the aggregation-prone
regions in monomers of this amyloidogenic protein.
Human lysozyme is a bacteriolytic enzyme. According to the
Phillips mechanism,59 the amino acid side chains glutamic acid
35 (Glu35) and aspartate 52 (Asp52) have been found to be
critical to the activity of this enzyme. Our docking study
predicted that the binding site for myricetin on HEWL was
clustered around many residues, such as Asn44, Asn46, Asp52,
Asn59 and Glu35, Ala107, Val109, and Trp62 and Trp63. Thus,
it is possible that myricetin docking with lysozyme could inhibit
its physiological functions to some extent; however, detailed
inhibitory studies need to be carried out to determine at what
concentration of myricetin is safe and efficient for dietary
flavonol consumption or as a drug candidate. It is important to
note that fibrillar tangles as well as amorphous aggregates can be
cytotoxic;60,61 also, a recent study on HEWL amorphous
aggregates has demonstrated that Cu(II) directs formation of
toxic amorphous aggregates resulting in inhibition of HEWL
fibrillation under alkaline-salt-mediated conditions.62 The
potential cytotoxicity of amorphous aggregates of HEWL
needs to be assessed in detail to fully appreciate the potential
of myricetin as a drug candidate.
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